EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis

Hermann Eichler, Nora V Butta, Anne Riddell, Cecilia Augustsson, Marianne Kjalke, Kasper Jensen, Andrea Paramo-Florencio, Jan Astermark, Pratima Chowdary, Victor Jiménez-Yuste

Haemophilia · 2026

DOI: 10.1111/hae.70203 ↗

At a glance

Journal article in Haemophilia, 2026. Written by Hermann Eichler and 9 co-authors. Institution: Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg, Germany. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Thrombelastography, Blood Coagulation, Hemophilia A. 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novo Nordisk A/S.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Rotational thromboelastometry (ROTEM) aims to measure the coagulation potential in whole blood. Concizumab, an anti‐tissue factor pathway inhibitor (TFPI) antibody for prophylaxis in haemophilia, enhances tissue factor (TF)‐initiated coagulation by preventing inhibition of activated factor X (FXa), thus increasing thrombin generation.

Objectives

To evaluate a modified ROTEM assay for monitoring patients on concizumab prophylaxis.

Methods

The TF reagent (r_exTEM) was diluted 50,000‐fold to make the ROTEM assay sensitive to haemophilia and to concizumab. The effect of concizumab was evaluated in the modified ROTEM in haemophilia A (HA)‐like blood (normal blood with added anti‐FVIII antibody). ROTEM analysis was performed in blood from patients participating in the explorer7/8 trials during 24 weeks of concizumab prophylaxis. Rotrol N plasma was used as quality control.

Results

In vitro experiments showed concizumab concentration‐dependent reduction in clot time (CT) and increase in clot development (α‐angle) in HA‐like blood. At three of four clinical sites, CT and clot development were stable, variance of the control plasma was ≤12.4% and TF content of the diluted reagent (r_exTEM) was consistent. At these three sites, the correlation between CT versus concizumab exposure, free TFPI and thrombin generation assay parameters was weak (‐0.508 to +0.359). Prothrombin time positively correlated with CT (0.523) and negatively correlated with α‐angle (‐0.659).

Conclusion

Due to the poor correlation between ROTEM parameters, concizumab exposure, free TFPI and thrombin generation parameters and the lack of consistent and reliable performance of the modified ROTEM assay, it cannot be recommended for general monitoring of patients on concizumab prophylaxis.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedThrombelastographyBlood CoagulationHemophilia AHumansBlood Coagulation TestsMale

Author keywords

blood coagulation testsconcizumabhaemophilia Ahaemophilia Bhaemostasisthromboelastometry

Substances

Antibodies, Monoclonal, Humanizedconcizumab

Authors and institutions

  • Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg, Germany.
  • Department of Haematology, La Paz University Hospital, Coagulopathies and Disorders of Haemostasis Group IdiPaz, Madrid, Spain.
  • KD Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
  • Health Services Laboratory, London, UK.
  • Department of Clinical Chemistry and Pharmacology, University and Regional Laboratories Region Skåne, Malmö, Sweden.
  • Novo Nordisk A/S, Måløv, Denmark.

Funding

  • Novo Nordisk A/S

Cite

APA

Eichler, H., Butta, N. V., Riddell, A., Augustsson, C., Kjalke, M., Jensen, K., Paramo-Florencio, A., Astermark, J., Chowdary, P., & Jiménez-Yuste, V. (2026). Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis. Haemophilia. https://doi.org/10.1111/hae.70203

Vancouver

Eichler H, Butta NV, Riddell A, Augustsson C, Kjalke M, Jensen K, et al. Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis. Haemophilia. 2026. doi:10.1111/hae.70203

BibTeX
@article{Eichler2026,
  author = {Eichler, Hermann and Butta, Nora V and Riddell, Anne and Augustsson, Cecilia and Kjalke, Marianne and Jensen, Kasper and Paramo-Florencio, Andrea and Astermark, Jan and Chowdary, Pratima and Jiménez-Yuste, Victor},
  title = {Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70203}
}
Start for free →